Navigation Links
Mylan Acquisition of Agila Receives Approval from India's Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs

PITTSBURGH, Sept. 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its proposed acquisition of the Agila injectables businesses from Strides Arcolab Limited (BSE: 532531, NSE: STAR) has received approval from India's Foreign Investment Promotion Board (FIPB). Subsequently, the transaction also received approval from the Cabinet Committee on Economic Affairs (CCEA). The transaction is expected to close in the fourth quarter of 2013, subject to remaining regulatory approvals and certain closing conditions.

Mylan CEO Heather Bresch commented, "We are very pleased to have received all outstanding Indian pre-merger regulatory approvals for the Agila transaction, especially considering the increased government regulation and oversight with respect to foreign investment in India.  We look forward to completing the acquisition in the coming months, which we believe will establish Mylan as a global injectables leader, with a significantly expanded and strengthened injectables portfolio, pipeline, platform and capabilities."

This press release includes statements that constitute "forward-looking statements," including with regard to the consummation of the planned transaction and Mylan's expected future performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: factors relating to satisfaction of the conditions to the consummation of the transaction, including remaining regulatory approvals; the impact and effects of legal or regulatory proceedings, actions or changes; general market perception of the transaction; uncertainties and matters beyond the control of management; the ability of the company to achieve the synergies or other benefits anticipated as a result of the acquisition; any conditions imposed upon the company in connection with obtaining regulatory approvals; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
2. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
3. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
4. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
5. Roger Graham Named President of Mylan Specialty
6. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
7. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
8. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
9. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
10. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
11. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become ... invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
Breaking Medicine News(10 mins):